ArticleInternational journal of ophthalmology2018
A retrospective study of 2228 cases with eyelid tumors.
Article in International journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 64 citations in OpenAlex.
- Giant and atypical eccrine tumors of the eyelid: A clinicopathologic analysis.Indian journal of ophthalmology · 2026Article
- Cholesterol metabolism dysregulation in eyelid sebaceous gland carcinoma and its clinical significance.Indian journal of ophthalmology · 2026Article
- Article
- Article
- Histopathological spectrum of ocular masses in a tertiary eye center in Northern China: a 12-year retrospective analysis.Frontiers in medicine · 2026Article
- Elongated, Pedunculated Verruca Vulgaris of Both Upper Eyelids: A Rare Bilateral Presentation.Cureus · 2025Article
- Deep learning-based mobile application for efficient eyelid tumor recognition in clinical images.NPJ digital medicine · 2025Article
- The correlation of clinical and histopathological features of eyelid malignancies: a 5-year retrospective study in Vietnam.International ophthalmology · 2025Observational
- Eyelid disorders and morphologies among older individuals: a cross-sectional survey in China.International journal of ophthalmology · 2025Article
- Impact of clinicopathological features of meibomian gland adenocarcinoma on the outcomes of surgical resection combined with eyelid reconstruction.American journal of cancer research · 2025Article
- Upper and Lower Eyelid Malignancies: Differences in Clinical Presentation, Metastasis, and Treatment.Archives of dermatological research · 2024Review
- Sebaceous hyperplasia of the eyelid: A comprehensive case report and literature review.Heliyon · 2024Article
- Comparison of the clinical characteristics of benign and malignant eyelid lesions: an analysis of 1423 eyelid lesions, compared between ophthalmology department and plastics department.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Squamous cell carcinoma of the eyelid.Japanese journal of clinical oncology · 2024Article
- Artificial intelligence and machine learning a new frontier in the diagnosis of ocular adnexal tumors: A review.SAGE open medicine · 2024Review
- [Diagnosis and treatment of benign eyelid tumors].Die Ophthalmologie · 2023Review
- Guidelines for the application of artificial intelligence in the diagnosis of anterior segment diseases (2023).International journal of ophthalmology · 2023Article
- Two Advancement Flaps for Eyelid Margin Reconstruction of Small and Medium Defects and a Novel Design to Reduce Ocular Injury.Clinical, cosmetic and investigational dermatology · 2023Article
- Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features.International journal of ophthalmology · 2023Article
- Eyelid malignancies in young individuals: clinical peculiarities.International ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe the histopathologic and clinical features of eyelid tumor cases from Tianjin Eye Hospital during 2002 to 2015.
methodsIn this retrospective study, a total of 2228 cases of eyelid tumors with pathologic diagnoses were enrolled. The eyelid tumors were classified into three groups according to tumor origin: epidermal, adnexal and miscellaneous, including melanocytic, neural and vascular lesions. Inflammatory tumor-like lesions were excluded. The clinical characteristics of the eyelid tumors were analyzed, including age, gender and lesion location.
resultsMost eyelid tumors were epidermal in origin (1080, 48.5%), followed by miscellaneous (885, 39.7%) and adnexal tumors (263, 11.8%). Among all the tumors, 292 (13.1%) were malignant lesions, 1910 (85.7%) benign and 26 (1.1%) premalignant lesions. Most malignant tumors originated from epidermal cells (60.0%), followed by adnexal cells (34.6%). The most common malignant tumors were basal cell carcinomas (56.5%) followed by sebaceous carcinoma (34.6%), squamous cell carcinomas (3.8%) and lymphoma/plasmocytoma (1.7%). The benign and premalignant eyelid lesions mostly originated from epidermal cells (46.4%) followed by miscellaneous cell sources (45.2%), including melanocytic nevus (33.8%), seborrheic keratosis (13.7%), squamous cell papilloma (13.0%) and epidermal cysts (11.5%).
conclusionEyelid tumors are mostly epithelial in origin. Benign tumors are significantly more common than malignant tumors with an obvious female predominance, and the most frequent malignant tumor are basal cell carcinoma, sebaceous carcinoma and squamous cell carcinomas. The tumor clinical features varied among the different subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.